Inluriyo is a drug owned by Eli Lilly And Co. It is protected by 2 US drug patents filed in 2025 out of which none have expired yet. Inluriyo's patents will be open to challenges from 25 September, 2029. Based on its patents and exclusivities, its generic launch date is estimated to be Jul 11, 2039. Details of Inluriyo's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents protect the active ingredient(API) of the drug. Only drug patent owner can launch products that use this active ingredient until these patents expire. | |||
| US10654866 | Selective Estrogen Receptor Degraders |
Jul, 2039
(13 years from now) | Active |
| US11117902 | Selective Estrogen Receptor Degraders |
Jul, 2039
(13 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease
the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that drug.
Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in the
patent process of
the drug which can give an idea of how early a drug's generic could be available. The next section
provides a list of
recent legal activities on Inluriyo's patents.
Latest Legal Activities on Inluriyo's Patents
Given below is the list of recent legal activities going on the following patents of Inluriyo.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 20 Feb, 2025 | US11117902 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 20 Oct, 2023 | US10654866 |
| Patent Issue Date Used in PTA Calculation | 14 Sep, 2021 | US11117902 |
| Recordation of Patent Grant Mailed | 14 Sep, 2021 | US11117902 |
| Email Notification | 26 Aug, 2021 | US11117902 |
| Issue Notification Mailed | 25 Aug, 2021 | US11117902 |
| Dispatch to FDC | 09 Aug, 2021 | US11117902 |
| Application Is Considered Ready for Issue | 09 Aug, 2021 | US11117902 |
| Issue Fee Payment Received | 06 Aug, 2021 | US11117902 |
| Issue Fee Payment Verified | 06 Aug, 2021 | US11117902 |
FDA has granted several exclusivities to Inluriyo. Till the time
these exclusivities
are active, no other company can market a generic or bioequivalent version of Inluriyo, regardless of the status of it's patents. These exclusivities hence play a crucial role in
delaying the generic
launch. Given below are details of the exclusivities granted to
Inluriyo.
Exclusivity Information
Inluriyo holds 1 exclusivities out of which none have expired. Its last outstanding exclusivity is set to expire in 2030. Details of Inluriyo's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 25, 2030 |
US patents provide insights into the exclusivity only within the United States, but
Inluriyo is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Inluriyo's family patents as well as insights into
ongoing legal events
on those patents.
Inluriyo's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Inluriyo's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Jul 11, 2039 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Inluriyo Generics:
There are no approved generic versions for Inluriyo as of now.
About Inluriyo
Inluriyo is a drug owned by Eli Lilly And Co. Inluriyo uses Imlunestrant Tosylate as an active ingredient. Inluriyo was launched by Eli Lilly in 2025.
Approval Date:
Inluriyo was approved by FDA for market use on 25 September, 2025.
NCE-1 date:
NCE-1 date also known as the four year date occurs four years after the original drug approval and marks the first opportunity for a generic manufacturer to file an ANDA with a Paragraph IV certification. This is the earliest point when generic competition might begin, provided the challenge is successful. Since the approval date for Inluriyo is 25 September, 2025, its NCE-1 date is estimated to be 25 September, 2029.
Active Ingredient:
Inluriyo uses Imlunestrant Tosylate as the active ingredient. Check out other Drugs and Companies using Imlunestrant Tosylate ingredient
Dosage:
Inluriyo is available in tablet form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 200MG BASE | TABLET | Prescription | ORAL |